Written by: Katie Carter, PharmD, BCPS, Indiana University Health
Download Here

Olaparib (Lynparza) is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is currently FDA approved as targeted therapy for BRCA-mutated breast cancer and ovarian cancer.  This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding dose adjustment.
Continue reading Olaparib in BRCA-mutated Breast, Ovarian and Pancreatic Cancer

Read More

Written by: Martina Fraga, PharmD
Download Here

This purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.

Continue reading Ovarian Cancer: PARP Inhibitor Eligibility

Read More

Written by: Michelle Phillips, PharmD, University of Rochester Medical Center
Download Here

The purpose of this PQI is to highlight key criteria for appropriate monitoring, dosing, and administration to improve the dispensing and management of patients taking niraparib (Zejula).

Continue reading Niraparib: dose modifications based on weight and platelet counts

Read More